Compounds > hydroxyurea
Page last updated: 2024-10-28

hydroxyurea and Viremia

hydroxyurea has been researched along with Viremia in 17 studies

Viremia: The presence of viruses in the blood.

Research Excerpts

ExcerptRelevanceReference
"The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination."9.11Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005)
"The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination."5.11Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005)
" Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <."2.70Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002)
"Hydroxyurea was found to induce lymphopenia (-124 x 10(6)/l)."2.69A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. ( Bernasconi, E; Bucher, HC; Hirschel, B; Iten, A; Leduc, D; Malinverni, R; Opravil, M; Perrin, LH; Rutschmann, OT; Sudre, P; Vernazza, PL; Yerly, S, 1998)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (41.18)18.2507
2000's10 (58.82)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lafeuillade, A2
Poggi, C2
Hittinger, G1
Counillon, E1
Emilie, D1
Foli, A4
Maserati, R2
Barasolo, G1
Castelli, F1
Tomasoni, L1
Migliorino, M1
Maggiolo, F1
Pan, A1
Paolucci, S1
Scudeller, L1
Tinelli, C3
D'Aquila, R1
Lisziewicz, J6
Lori, F6
Pollard, RB2
Whitman, L1
Bakare, N1
Blick, G1
Shalit, P1
Peterson, D1
Tennenberg, A1
Schrader, S1
Rashbaum, B1
Farthing, C1
Herman, D1
Norris, D1
Greiger, P1
Frank, I1
Groff, A1
Lova, L1
Asmuth, D1
Nunnari, G1
Leto, D1
Sullivan, J1
Xu, Y1
Mehlman, KE1
Kulkosky, J1
Pomerantz, RJ1
Lewin, SR1
Murray, JM1
Solomon, A1
Wightman, F1
Cameron, PU1
Purcell, DJ1
Zaunders, JJ1
Grey, P1
Bloch, M1
Smith, D1
Cooper, DA1
Kelleher, AD1
Pellegrino, P1
Profizi, N1
Thiebaut, C1
Simonelli, C1
Comar, M1
Zanussi, S1
De Paoli, P1
Tirelli, U1
Giacca, M1
De Antoni, A2
Malykh, AG1
Minoli, L1
Padrini, D1
Degli Antoni, A1
Barchi, E1
Jessen, H2
Wainberg, MA1
Gallo, RC1
Nokta, M1
Rossero, R1
Loesch, K1
Rutschmann, OT1
Opravil, M1
Iten, A1
Malinverni, R1
Vernazza, PL1
Bucher, HC1
Bernasconi, E1
Sudre, P1
Leduc, D1
Yerly, S1
Perrin, LH1
Hirschel, B1
Lieberman, J1
Clerici, M1
Barreiro, P1
de Mendoza, C1
Soriano, V1
González-Lahoz, J1
Lewis, MG1
Xu, J1
Varga, G1
Zinn, DE1
Crabbs, C1
Wagner, W1
Greenhouse, J1
Silvera, P1
Yalley-Ogunro, J1
Stranford, SA1
Ong, JC1
Martinez-Marino, B1
Busch, M1
Hecht, FM1
Kahn, J1
Levy, JA1
Reed, W1
Vichinsky, EP1
Zala, C1
Salomon, H1
Ochoa, C1
Kijak, G1
Federico, A1
Perez, H1
Montaner, JS1
Cahn, P1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Exploratory, Open-Label, Randomized Trial to Evaluate the Ability of Interleukin-2 (IL-2) to Enhance HIV-Specific Immunity and Influence the Time to Virologic Relapse Following Withdrawal of Potent Antiretroviral Therapy[NCT00038259]21 participants InterventionalCompleted
Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy [NCT00918840]16 participants (Actual)Observational2009-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for hydroxyurea and Viremia

ArticleYear
Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Bacteremia; Blood Group Antigens; Blood Substitutes; B

2001

Trials

11 trials available for hydroxyurea and Viremia

ArticleYear
Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
    The Journal of infectious diseases, 2003, Nov-15, Volume: 188, Issue:10

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; DNA, Viral; Drug Administration

2003
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Antiviral therapy, 2004, Volume: 9, Issue:1

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Resistan

2004
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Drug-Re

2005
Seminal reservoirs during an HIV type 1 eradication trial.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:9

    Topics: Amino Acid Sequence; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Viral;

2005
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
    Journal of acquired immune deficiency syndromes (1999), 2008, Feb-01, Volume: 47, Issue:2

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydrox

2008
No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
    AIDS (London, England), 1997, Volume: 11, Issue:10

    Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; RN

1997
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
    The Journal of infectious diseases, 1997, Volume: 176, Issue:4

    Topics: Anti-HIV Agents; Didanosine; DNA, Complementary; Drug Resistance, Microbial; Drug Therapy, Combinati

1997
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
    AIDS research and human retroviruses, 1997, Nov-01, Volume: 13, Issue:16

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Cells; Didanosine; Dose-R

1997
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    AIDS (London, England), 1998, May-28, Volume: 12, Issue:8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Double-Blind Method; Drug

1998
Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    AIDS research and human retroviruses, 1999, May-01, Volume: 15, Issue:7

    Topics: Anti-HIV Agents; CD3 Complex; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph

1999
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-01, Volume: 29, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf

2002

Other Studies

5 other studies available for hydroxyurea and Viremia

ArticleYear
Hydroxyurea and HIV-1 viraemia.
    AIDS (London, England), 1995, Volume: 9, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV In

1995
Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
    AIDS research and human retroviruses, 1997, Dec-10, Volume: 13, Issue:18

    Topics: Adult; Anti-HIV Agents; Antigens, CD; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; F

1997
Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.
    AIDS (London, England), 2000, Jan-28, Volume: 14, Issue:2

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; Humans; H

2000
Control of SIV rebound through structured treatment interruptions during early infection.
    Science (New York, N.Y.), 2000, Nov-24, Volume: 290, Issue:5496

    Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-

2000
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Jan-16, Volume: 98, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphoc

2001